Overall survival (OS) and disease-free progression (PFS) are two important indicators for evaluating the therapeutic effect of patients with non-small cell lung cancer. OS is the gold standard for clinical research endpoints. PFS is a surrogate indicator, which is susceptible to bias. Wh...

The cancer research community underwent a huge change in 2013, because a strategy that had been in the making for decades finally established its potential. There have been encouraging results from clinical trials of cancer immunotherapy. In cancer immunotherapy, the target of treatment is the bo...

In addition to the increasing incidence of cancer in developing countries and newly industrialized countries, the incidence of cancer in Western developed countries led by the United States also remains high. At the same time, new anti-cancer drugs such as monoclonal antibodies and kinase inhib...

According to data released by the International Agency for Research on Cancer of the World Health Organization on December 12, 2013, there were 14.1 million new cancer cases worldwide in 2012, a rapid increase, and the cancer situation in Asian countries became the focus. The 131021-1 In...